Printer Friendly

DRAXIS Receives Brazilian Approval for Anipryl.

Business Editors

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Oct. 17, 2000

DRAXIS Health Inc. (TSE:DAX.)(NASDAQ:DRAX) today announced that Anipryl(R), a veterinary prescription medication licensed to Pfizer Inc. (NYSE:PFE), has been cleared by the Brazilian Ministerio da Agricultura e de Abastecimento for the treatment of uncomplicated pituitary-dependent hyperadrenocorticism (PDH or Cushing's disease) and age associated cognitive dysfunction (CDS) in dogs.

Brazil represents the fifth jurisdiction to approve Anipryl(R) for these two indications.

Dr. Martin Barkin, the President and CEO of DRAXIS Health stated: "We are pleased to report these positive developments regarding Anipryl(R). Jurisdictional approvals have the effect of increasing the potential worldwide sales base for Anipryl(R), currently available in Canada and the U.S. only. Once launched in other countries we expect that derivative royalties and manufacturing margins for DRAXIS will correspondingly increase."

Dr. Barkin continued, "In accordance with the terms of our agreement, Pfizer will pay DRAXIS USD$100,000 if it chooses to accept transfer of the Brazilian registration. Alternatively, Pfizer may designate another jurisdiction for which this milestone will apply."

In December 1997, DRAXIS entered into a worldwide comprehensive alliance with Pfizer Inc. with respect to Anipryl(R). Under the terms of the alliance, DRAXIS licensed the right to market, sell and distribute Anipryl(R) globally in return for milestones, royalty payments, a supply agreement and a research and development (R&D) collaboration.

DRAXIS Health Inc. is a diversified speciality pharmaceutical company operating in three niche markets: Radiopharmaceuticals (DRAXIMAGE), Canadian sales and marketing (DRAXIS Pharmaceutica) and Companion Animal Health (through its global alliance with Pfizer Inc.). DRAXIS supports its own as well as third party manufacturing requirements through its subsidiary, DRAXIS Pharma, located in Kirkland, Quebec.

Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties, which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, clinical trial results, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time-to-time in the Company's filings with the U.S. Securities and Exchange Commission and Canadian securities authorities.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Oct 17, 2000
Previous Article:TownPages Subsidiary Appoints New Board, Realigns Its Kiosk Business Focus & Restructures Management.
Next Article:Vasogen Announces Positive Clinical Results in Psoriasis.

Related Articles
Draxis to acquire Toronto Medical -- will double Draxis revenues.
DRAXIS - FDA Clears Anipryl - selegiline hydrochloride - For Canine Cognitive Dysfunction Syndrome - New Indication to be Launched in January 1999.
DRAXIS - Receives Australian Approval of AniprylR Selegiline Hydrochloride For Canine Cognitive Dysfunction Syndrome and Cushing's Disease.
DRAXIS - Receives Australian Approval of AniprylR selegiline hydrochloride For Canine Cognitive Dysfunction Syndrome and Cushing's Disease.
DRAXIS Receives US$13 Million in Milestones from Pfizer.
DRAXIS Health Reports Fourth Quarter and Full Year 1998 Results; Anipryl Milestones Boost Revenues and Contribute to EPS of $0.16 for the Year.
DRAXIS and Pfizer Amend License Terms for Anipryl in Europe.
DRAXIS Receives New Zealand Approval for Anipryl.
DRAXIS To Receive An Additional $2.0 Million From Anipryl Collaboration.
DRAXIS And Pfizer Amend Licensing Terms For Anipryl'R'.

Terms of use | Copyright © 2015 Farlex, Inc. | Feedback | For webmasters